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Warfarin Versus Aspirin in Paroxysmal
Atrial Fibrillation
I read with interest the article on the relation between fibrinocoagu-
lation activity and duration of atrial fibrillation in patients with
paroxysmal atrial fibrillation by Sohara et al. (1). They concluded that
anticoagulant therapy, “including suppression of platelet activity,” is
indicated when paroxysmal atrial fibrillation lasts for .12 h. May I
point out that suppression of platelet activity is not part of anticoag-
ulant therapy? It might also be of interest to recall the recent reports
of their compatriots (2,3) on the effects of aspirin on status of thrombin
generation in atrial fibrillation.
These investigators (2,3) measured plasma levels of molecular
markers for platelet activity (platelet factor 4, beta-thromboglobulin)
and the status of thrombin generation (thrombin–antithrombin III
complex, fibrinopeptide A, F112 fragment) and fibrinolysis (D-dimer,
plasma-alpha 2–plasmin inhibitor complex) before and after aspirin
administration for 14 days in patients with nonvalvular atrial fibrilla-
tion. They noted that basal levels of platelet factor 4 and beta-
thromboglobulin did not differ significantly between patients with
atrial fibrillation and normal subjects. After 14 days of aspirin therapy,
plasma levels of these markers in the patients had decreased signifi-
cantly. In contrast, basal levels of fibrinopeptide A and thrombin–
antithrombin III complex were significantly higher in patients with
atrial fibrillation than in normal subjects. However, no significant
reductions in plasma levels of these markers in the patients were
observed on day 14 of aspirin treatment.
These findings thus demonstrate that thrombin activity is aug-
mented in patients with nonvalvular atrial fibrillation. Although aspirin
significantly suppressed the platelet activity, it did not affect the
coagulation system. These finding also suggest that the effectiveness of
aspirin in the Stroke Prevention in Atrial Fibrillation study (4) may
have been due to the suppression of platelet activity, not to the
suppression of thrombin generation, although they detected no in-
creased platelet activity in patients with atrial fibrillation. Alterna-
tively, the effectiveness of aspirin may have been due to the prevention
of cerebral thrombosis, but not cardiogenic embolism. These results
therefore support the premise that the administration of an anticoag-
ulant agent is more appropriate than suppression of platelet activity by
aspirin for preventing systemic embolism in patients with nonvalvular
atrial fibrillation, whether chronic or paroxysmal.
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Reply
I thank Cheng for his interest in our recent article. As he points out,
aspirin significantly suppressed platelet activity but did not affect the
coagulation system (1). Therefore, we agree that the sentence in the
conclusion of our article, “anticoagulant therapy, including suppression
of platelet activity, is required when AF [atrial fibrillation] continues for
.12 h,” was ambiguous and caused misunderstanding. However, we
wished to indicate that not only antithrombotic therapy but also
antiplatelet therapy is important for preventing ischemic stroke, for the
following reasons:
1. Disturbance of blood flow during atrial fibrillation leads to an
increase in shear flow, platelet adhesion and aggregation and the
release reaction. Subsequently, thrombin generation is accelerated in
the presence of platelet factor 3; thrombin converts fibrinogen into
fibrin; and emoboli are then generated (2–4). In other words, in-
creased platelet activity plays an important role in the primary phase of
thrombus formation.
2. Yamamoto et al. (1) indicated that platelet activity in patients
with atrial fibrillation was not accelerated. In contrast, some investi-
gators have reported that it was accelerated (5–7). It is difficult to
explain this discrepancy, but it may be due to differences in age or time
from onset of atrial fibrillation.
3. In the Stroke Prevention in Atrial Fibrillation (SPAF-I,II) study
(8,9) it was shown that warfarin may be more effective than aspirin for
prevention of ischemic stroke in patients atrial fibrillation. However,
younger patients had a low rate of stroke when treated with aspirin.
The effectiveness of aspirin may have been due to the suppression of
platelet activity. Furthermore, Yamamoto et al. (1) reported that
aspirin significantly suppressed platelet function.
According to these reports, the acceleration of platelet activity in
the present study may indicated that atrial fibrillation causes not only
cerebral embolism but also cerebral thrombosis, and thus antithrom-
botic and antiplatelet combination therapy may prevent ischemic
stroke more effectively. Therefore, the sentence pointed out in our
article seems to be adequately expressed as “anticoagulant therapy and





Kagoshima City 890, Japan
References
1. Yamamoto K, Ikeda T, Fukazawa H, Shimanda K. Effects of aspirin on status of thrombin
generation in atrial fibrillation. Am J Cardiol 1996;77:528–30.
2. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and
formation of mural thrombi. Microvasc Res 1973;5:167–79.
3. Turitto VT, Weiss HJ. Red blood cells: their role in thrombosis formation. Science
1980;207:541–3.
4. Mustard JF, Kinlough-Rathborn RL, Packham MA. Recent status of research in the
pathogenesis of thrombosis. Thromb Diath Haemorrh Suppl 1974;59:157–88.
5. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and
the increased risk of strokes in nonvalvular atrial fibrillation. Stroke 1990;21:47–51.
6. Shah AB, Beamer N, Caull BM. Enhanced in vivo platelet activation in subtypes of ischemic
stroke. Stroke 1985;16:643–7.
7. Yamaguchi K, Furui H, Taniguchi N, Sotobata I. Plasma b-thromboglobulin and platelet
factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J 1986;27:481–7.
8. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in Atrial Fibrilla-
tion study: final results. Circulation 1991;84:527–39.
9. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for preven-
tion of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II
study. Lancet 1994;343:687–91.
1702 LETTERS TO THE EDITOR JACC Vol. 31, No. 7
June 1998:1698–702
